

GLAXOSMITHKLINE PLC

Form 6-K

January 04, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending January 2011

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.

On 31 December 2010, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £12.55 per Ordinary share and \$39.18 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 October 2010 to 31 December 2010:

	Ordinary Shares	American Depository Shares (ADSs)
Non Executive Director		
Sir Christopher Gent	2,689.24	
Prof. Sir Roy Anderson	672.31	
Dr Stephanie Burns		390.65
Mr Lawrence Culp		781.30
Sir Crispin Davis	2,490.04	
Sir Deryck Maughan		781.30
Mr James Murdoch	2,091.63	
Dr Daniel Podolsky		820.36
Mr Tom de Swaan	921.32	
Sir Robert Wilson	672.31	

The Company and the Non-Executive Directors were informed of these allocations on 4 January 2011.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary
4 January 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 4, 2011

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc